Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Se Ik Kim

Showing results (41-50 of 138) with videos related to

Pageof 14
Sort By:
Cancer Research and Treatment|November 8, 2024
Time-Trend Analysis and Risk Factors for Niraparib-Induced Nausea and Vomiting in Ovarian Cancer: A Prospective StudyYoung Wook Jeong, Dongkyu Eugene Kim, Ji Hyun Kim, et al.
Cancers|July 13, 2024
Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP InhibitorsJi Hyun Kim, Eun Taeg Kim, Se Ik Kim, et al.
Oncogene|August 15, 2019
Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cellsYoungjin Han, Boyun Kim, Untack Cho, et al.
Journal of Gynecologic Oncology|September 19, 2025
Erratum: The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organizationDavid Tan, Noriko Fujiwara, Keiichi Fujiwara, et al.
Frontiers in Oncology|June 14, 2021
Enhanced Susceptibility to Breast Cancer in Korean Women With Elevated Serum Gamma-Glutamyltransferase Levels: A Nationwide Population-Based Cohort StudyAeran Seol, Wenyu Wang, Se Ik Kim, et al.
Gynecologic Oncology|February 14, 2022
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective studyJunsik Park, Se Ik Kim, Soo Young Jeong, et al.
In Vivo (Athens, Greece)|April 30, 2024
Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian CancerAeran Seol, Se Ik Kim, Hee Yeun Yoon, et al.
Translational Oncology|August 11, 2024
Elevation of circulating neutrophil extracellular traps in endometrial cancer: Poor prognostic value of cell-free double-stranded DNAYeonju Seo, Se Ik Kim, Sang Hoon Song, et al.
Gynecologic Oncology|December 17, 2023
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancerJi Hyun Kim, Se Ik Kim, Eun Young Park, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 15, 2020
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancerSe Ik Kim, Eun Ji Lee, Maria Lee, et al.
Pageof 14

Showing results (41-50 of 138) with videos related to

Sort By:
Pageof 14
Cancer Research and Treatment|November 8, 2024
Time-Trend Analysis and Risk Factors for Niraparib-Induced Nausea and Vomiting in Ovarian Cancer: A Prospective StudyYoung Wook Jeong, Dongkyu Eugene Kim, Ji Hyun Kim, et al.
Cancers|July 13, 2024
Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP InhibitorsJi Hyun Kim, Eun Taeg Kim, Se Ik Kim, et al.
Oncogene|August 15, 2019
Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cellsYoungjin Han, Boyun Kim, Untack Cho, et al.
Journal of Gynecologic Oncology|September 19, 2025
Erratum: The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organizationDavid Tan, Noriko Fujiwara, Keiichi Fujiwara, et al.
Frontiers in Oncology|June 14, 2021
Enhanced Susceptibility to Breast Cancer in Korean Women With Elevated Serum Gamma-Glutamyltransferase Levels: A Nationwide Population-Based Cohort StudyAeran Seol, Wenyu Wang, Se Ik Kim, et al.
Gynecologic Oncology|February 14, 2022
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective studyJunsik Park, Se Ik Kim, Soo Young Jeong, et al.
In Vivo (Athens, Greece)|April 30, 2024
Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian CancerAeran Seol, Se Ik Kim, Hee Yeun Yoon, et al.
Translational Oncology|August 11, 2024
Elevation of circulating neutrophil extracellular traps in endometrial cancer: Poor prognostic value of cell-free double-stranded DNAYeonju Seo, Se Ik Kim, Sang Hoon Song, et al.
Gynecologic Oncology|December 17, 2023
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancerJi Hyun Kim, Se Ik Kim, Eun Young Park, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 15, 2020
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancerSe Ik Kim, Eun Ji Lee, Maria Lee, et al.
Pageof 14